Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry

BACKGROUND: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Prostate Cancer Prostatic Dis
Glavni autori: Francini, Edoardo, Gray, Kathryn P., Shaw, Grace K., Evan, Carolyn P., Hamid, Anis A., Perry, Caitlin E., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher J.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869825/
https://ncbi.nlm.nih.gov/pubmed/30643173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-018-0121-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items